Connect with us

Business

Indiva Ltd (OTCMKTS:NDVAF) Signs A Financing And A White Label Production Agreement With Dycar Pharmaceuticals Ltd: Produces Cannabis Products Under Dycar Brand

Published

on

Indiva Ltd (OTCMKTS:NDVAF) signed a white label manufacturing accord with Dycar Pharmaceutical Ltd. As per the deal, the company will produce high-quality cannabis products under the Dycar brand from its London, Ontario licensed facility. Indiva will also receive financing of up to $4 million from Dycar.

Option to extend the deal

Indiva will repay the debt through its services to Dycar. It has an option to extend the deal for an additional two terms (minimum) at the sole discretion of Dycar. As a result, Indiva will get additional non-dilutive financing of up to $4.5 million.

CEO of Indiva, Niel Marotta, said the company is pleased to rope in a high-quality partner – Dycar into its B2B platform. Both firms share the same vision to deliver high-quality products to satisfy the market needs. He further said the company is excited to work with Dycar and bring innovative products that exceed the consumer and customer expectations.

Funding expected in mid-December 2019

Indiva expects the funding in mid-December 2019 subject to satisfying customary conditions that comprise receiving applicable third-party approvals and executing definitive agreements. The company also expects to receive financing of up to $4 million through unsecured convertible debentures. Each debenture is priced at $1000 and convertible to 5,000 common shares (at $0.20 for each share) of Indiva. The debenture holders will receive an interest of 10% and paid semi-annually (on December 31 and June 30). Issued debentures have a maturity of 36 months from the date of issue.

In Q3 2019, Indiva posted revenues of $185,539. The company received the nod for the distribution of pre-rolls, dry flower, and capsules to the customers in Quebec. It will also offer extraction services as per the accord signed in August 2019 to TerrAscend. Indiva will receive a minimum of 800 kg of dry flower annually from TerrAscend.

Marotta said the company is poised to report significant growth next year. He praised the strengths of his teams and contributions from partners for achieving commercial scale in such a short period. Indiva expects to meet the needs of 90% of the eligible customers by providing high-quality products.

Business

Pharmacyte Biotech Inc (OTCMKTS:PMCB) To Hit Is Major Milestones This Year

Published

on

Pharmacyte Biotech Inc (OTCMKTS:PMCB) is looking forward to achieving some major milestones in time to come. The shareholders have a lot to gain if the company achieves its set targets.

This business guru says 2020 is its year since it is time it hopes to achieve these major milestones. The milestones to be achieved are in line with the company’s leading therapy for the locally advanced, inoperable pancreatic cancer (LAPC).

Investors hoping to benefit from the achievement of milestones

Investors in the stock continue hoping for a price appreciation as the company upholds its focus, achieving the milestones. The company’s Investigational New Drug application (IND) is set to reach the FDA any time soon. This is the first milestone that the shareholders expect to be achieved this year.

Pharmacyte requires approval from the body to engage in the administration of the product. It will be in the company’s Phase 2b clinical trial that it will be administering the product to the patients.

The submission of an IND a few weeks later will be followed by another major development. This will probably be the achievement of the second milestone, which is the FDA’s response. A positive response will see the business guru start the clinical trials of the product.

The IND and matters surrounding it

Upon receiving the IND, the FDA will do as it usually does with the other submissions i.e. notify Pharmacyte. It will do that through an IND letter of acknowledgment. Usually, the FDA has about 30 days to review the submission and offer a response.

However, some things would result in the body doing things out of the ordinary. This is when the FDA realizes that the application in question is subject to some clinical hold. In such a case, the body is left with no other choice but6 to collect more information.

The business guru will be looking forward to seeing the IND go through. This will probably mark the start of shipping the product to the various investigators outlined in the IND application.

The prevailing condition has always been for the investigator to wait until the FDA approves the IND to take the next move. That would probably be the delivery of the therapy to humans.

Continue Reading

Business

Sugarmade Inc (OTCMKTS:SGMD) Clarifies That It Has Not Authorized Or Engaged Any Third Party For Promotional Activities

Published

on

Sugarmade Inc (OTCMKTS:SGMD) said it has not authorized or engaged any third-party for promotional activities of its common stock. The company is only aware of the news of unauthorized promotional activities through the communication of OTC Markets.

Sugarmade is not involved indirectly or directly

Sugarmade stated that it is not involved either indirectly or directly with the distribution, creation, or paid for the promotional materials related to its securities. It is not even known about such content or editorials for promotional activities. The company puts a heavyweight on marketing practices and investor relations.

Conducted due diligence

Sugarmade conducted due diligence into the unauthorized promotional activities involving its securities. The promotional activities comprised unvetted and incomplete information regarding its securities and business performance. After conducting an inquiry, the company said its directors, officers, or any beneficial owner of 10% of its common stock are not involved in the sale or purchase of its common stock in the past three months.

Authorized channels of information

Sugarmade issues press releases through corporate communications firm or NetworkNewsWire. The company has only engaged FN Press Wire, IR Pub LLC, and EHC Branding Agency for marketing related services, public relations, and investor relations in the last 12 months.

Enters the market of hemp extraction equipment

Sugarmade has entered the supply of laboratory and hemp extraction equipment. The company already started the supply of equipment for installation in a large facility in the eastern region of the US.

Jimmy Chan, Chief Executive Officer of Sugarmade, said the company is pleased to confirm the acceptance of initial components received from the producer and are in the transit to Western Kentucky. Sugarmade will record these revenues after delivery and installation in January this year.

East West BioPharma Group, Inc., an ordering entity, is constructing a laboratory and hemp extraction facility, which will have a daily distillate processing capacity of 1,000 hemp distillate. Sugarmade supplied high quality and highly efficient machines to meet the goal of East West Biopharma.

Sugarmade inked a pact with Chinese manufacturers, who have experience in the design and supply of equipment for the extraction of oils from terpenes, and medicinal plants.

Continue Reading

Business

Medipharm Labs Corp (OTCMKTS:MEDIF) Completes Initial Shipments Of Indica Vape Cartridges: Receives Amended License To Begin Production In Barrie

Published

on

Medipharm Labs Corp (OTCMKTS:MEDIF) has completed the first shipment under a cannabis 2.0 accord with 1193269 B.C. Ltd. The company is offering high-quality cannabis extracts and filling services through MediPharm Labs Inc (MLI), its wholly-owned subsidiary. MLI also distributes custom formulated Shelter Vape Cartridges under the Wafarer brand across the nation.  Shelter House Brand, which is managed by 1193269 B.C. Ltd, has developed the Wafarer brand for the customers to enjoy uncompromised tastes in sleek product design.

Expanding white label portfolio

CEO of MediPharm Labs, Pat McCutcheon, said the company is one of the first license holders to introduce quality assured cannabis concentrates to the consumers in Canada. The company will use its platform built over several years to expand the white label portfolio with Shelter that focuses on developing top-notch brands for the customers.

Receives a license amendment

Health Canada has granted an amendment to the license allowing MLI to commence the production in a recently expanded area of the specialized manufacturing facility based in Barrie, Ontario. With this amendment, the total licensed footprint is increased to 25,000 Sq. Ft. The company can use a large chunk of the manufacturing facility for cannabis activities that comprise research and development, testing and quality control of cannabis, downstream production/ packaging, and secure storage for the distribution and fulfillment of new orders and support new product formulations.

Pat said the amended license allows the company to unlock the recent investments in expanded capacity and advanced capabilities at an appropriate time. The company focuses on the white label business and scale up its platform to satisfy the demand of customers.

Meets GMP for medicinal products

The Australian TGA (Therapeutic Goods Administration) has informed Medipharm Labs that its manufacturing facility in Canada complies with GMP (Good Manufacturing Practice) for medicinal products. It helps the company to increase its manufacturing capabilities across the world.

Department of Health and Human Services in Victoria, Australia, has awarded the state licenses to MediPharm Labs Australia Pty. Ltd, a subsidiary of MediPharm Labs Corp, for cannabis substances. The company completed the initial construction of an extraction facility in Wonthaggi. It will use the new facility for testing, storing, and R&D of cannabis.

Continue Reading

FEATURED STORIES

Business3 days ago

Pharmacyte Biotech Inc (OTCMKTS:PMCB) To Hit Is Major Milestones This Year

Post Views: 212 Pharmacyte Biotech Inc (OTCMKTS:PMCB) is looking forward to achieving some major milestones in time to come. The...

Business4 days ago

Sugarmade Inc (OTCMKTS:SGMD) Clarifies That It Has Not Authorized Or Engaged Any Third Party For Promotional Activities

Post Views: 148 Sugarmade Inc (OTCMKTS:SGMD) said it has not authorized or engaged any third-party for promotional activities of its...

Business5 days ago

Medipharm Labs Corp (OTCMKTS:MEDIF) Completes Initial Shipments Of Indica Vape Cartridges: Receives Amended License To Begin Production In Barrie

Post Views: 224 Medipharm Labs Corp (OTCMKTS:MEDIF) has completed the first shipment under a cannabis 2.0 accord with 1193269 B.C....

Business6 days ago

Gold Leaf Distribution, A Subsidiary Of Kona Gold Solutions Inc (OTCMKTS:KGKG), Expects To Post Revenues of $1.5 Million In 2020

Post Views: 240 Gold Leaf Distribution, a subsidiary of Kona Gold Solutions Inc (OTCMKTS:KGKG), is expected to post revenues of...

Business7 days ago

Craig Fischer Of Demand Brands Inc (OTCPK:DMAN) Issues An Update To The Shareholders On Future Oil And Gas Operations

Post Views: 568 Craig Fischer, Chief Executive Officer of Demand Brands Inc (OTCPK:DMAN), is pleased to issue an update on...

BENEFITS OF CBD1 week ago

Benefits of CBD and Glaucoma

Post Views: 390 CBD oil found itself linked permanently with the treatment of eye diseases back in 1976. An octogenarian...

Whats Hot